NCT06884670: Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study

Sponsor: The First Affiliated Hospital with Nanjing Medical University. Phase: PHASE2. Conditions: Rectal Cancer